Second-line treatment for advanced liver cancer after immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs (SHR-1701 and apatinib) for people with advanced liver cancer that has gotten worse after first-line treatment with targeted therapy and immunotherapy. The goal is to see if this combination can help slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced or metastatic liver cancer that cannot be removed by surgery.
- You must have already received first-line treatment that combined targeted therapy and immunotherapy, and your cancer has progressed or you couldn't tolerate it.
- You must have at least one measurable tumor (a tumor that can be seen and measured on scans).
- You must be in good physical condition (able to take care of yourself) and have adequate organ function.
- You must not have been previously treated with apatinib or a PD-L1 checkpoint inhibitor (a type of immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Hear when a new Advanced Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.